WASHINGTON, May 11 -- National Institutes of Health has issued a notice called: Government Owned Inventions Available for License: Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1.
The notice was published in the Federal Register on May 11 by Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute.
Summary: The Eunice Kennedy ShriverNational Institute of Child Health and Human Development (NICHD) is actively seeking potential licensees interested in further developing these inhibitory transmembrane adapter proteins as targets for T-cell immunotherapy for the treatment of cancer, infectious diseases, and autoimmune diseases.
For more information, contact Inquiries related to this lic...